Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis
Kiran K. Motwani,Madeline Alizadeh,Ameer Abutaleb,Jennifer Grossman,Jennifer Wellington,Raymond K. Cross,Kirk Russ,Meena Bewtra,James Lewis,Raymond Cross,Uni Wong,Scott Snapper,Josh Korzenik,Shrinivas Bishu,Rick Duerr,Sumona Saha,Freddy Caldera,Laura Raffals,Richa Shukla,Themistocles Dassopoulos,Matthew Bohm,Poonam Beniwal-Patel,David Hudesman,Lauren Brook,Joel Pekow,Elizabeth Scoville,Matthew Cioba,Parakkal Deepak,SPARC-IBD investigators
DOI: https://doi.org/10.1007/s10620-024-08421-w
2024-04-07
Digestive Diseases and Sciences
Abstract:Patient-reported outcomes (PROs), such as the short CD activity index (sCDAI) and partial Mayo Score (PMS), are used to define clinical remission in IBD, but may not represent the true degree of inflammation and endoscopy is invasive. Non-invasive testing options include c-reactive protein (CRP) and fecal calprotectin (FCP).
gastroenterology & hepatology